Literature DB >> 8898962

Delineation of the minimal encephalitogenic epitope within the immunodominant region of myelin oligodendrocyte glycoprotein: diverse V beta gene usage by T cells recognizing the core epitope encephalitogenic for T cell receptor V beta b and T cell receptor V beta a H-2b mice.

N Mendel Kerlero de Rosbo1, A Ben-Nun.   

Abstract

The nature of the autoimmune T cell response to myelin oligodendrocyte glycoprotein (MOG), recently recognized as a potential target antigen in multiple sclerosis (MS), has not yet been characterized, in contrast to the T cell reactivity to other potential target antigens in MS such as myelin basic protein and proteolipid protein. Here, we show that the encephalitogenicity of the recombinant Ig-like domain of human MOG is associated, in H-2 b mice, with an immunodominant T cell reactivity against a single region of MOG spanning amino acids 35-55, accounting for the previously reported strong encephalitogenic activity of pMOG 35-55. A single injection of pMOG 35-55 with or without administration of pertussis toxin was sufficient to induce severe clinical experimental autoimmune encephalomyelitis (EAE) in H-2 b mice. Encephalitogenic pMOG 35-55-specific T cell lines derived from C3H.SW (V beta b) mice were diverse in their TCR V beta gene usage (V beta 1, V beta 6, V beta 8 and V beta 15), although V beta 8.2 was most predominantly expressed (48%). However, V beta 8 + T cells may only be part of the encephalitogenic MOG-specific T cell repertoire in H-2 b mice, as demonstrated by the susceptibility of C57L (V beta a) mice to disease induced by pMOG 35-55. Encephalitogenic T cell lines from V beta a mice were also diverse in their TCR V beta gene usage (V beta 1, V beta 2, V beta 6, V beta 14 and V beta 16). Such a heterogeneous TCT V beta gene expression by pMOG 35-55/I-A b-reactive T cells from both V beta a and V beta b H-2 b mice suggested multiple epitopes within pMOG 35-55. Analysis of the pattern of reactivity by pMOG 35-55-reactive T cells to a set of truncated peptides was not commensurate with independent nested epitopes, but revealed a requirement for recognition of a core sequence, YRSPFSRVV (pMOG 40-48). However, optimal stimulation was obtained with longer peptides, with each additional amino acid flanking either the N or the C terminus differentially increasing the stimulatory capacity of pMOG 40-48. Nonetheless, pMOG 40-48 was the minimal encephalitogenic epitope for both V beta a and V beta b mice. Thus, the T cell reactivity against the immunodominant encephalitogenic region of MOG is characterized by a diverse V beta gene usage and a requirement for the same core epitope. This pattern of reactivity may favor epitope-directed, rather than TCR-targeted, approaches to immunospecific therapy for MOG-related autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8898962     DOI: 10.1002/eji.1830261030

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  24 in total

1.  Molecular mimicry revisited: gut bacteria and multiple sclerosis.

Authors:  Fred C Westall
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

Review 2.  Manipulating antigenic ligand strength to selectively target myelin-reactive CD4+ T cells in EAE.

Authors:  Joseph J Sabatino; Kristen M Rosenthal; Brian D Evavold
Journal:  J Neuroimmune Pharmacol       Date:  2009-11-11       Impact factor: 4.147

Review 3.  Immune responses against the myelin/oligodendrocyte glycoprotein in experimental autoimmune demyelination.

Authors:  H C von Büdingen; N Tanuma; P Villoslada; J C Ouallet; S L Hauser; C P Genain
Journal:  J Clin Immunol       Date:  2001-05       Impact factor: 8.317

4.  Discrete TCR repertoires and CDR3 features distinguish effector and Foxp3+ regulatory T lymphocytes in myelin oligodendrocyte glycoprotein-induced experimental allergic encephalomyelitis.

Authors:  Phuong Nguyen; Wei Liu; Jing Ma; Jean N Manirarora; Xin Liu; Cheng Cheng; Terrence L Geiger
Journal:  J Immunol       Date:  2010-09-01       Impact factor: 5.422

5.  Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiology.

Authors:  Cecilia B Marta; Alfred R Oliver; Rebecca A Sweet; Steven E Pfeiffer; Nancy H Ruddle
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-19       Impact factor: 11.205

6.  Requirement for endocytic antigen processing and influence of invariant chain and H-2M deficiencies in CNS autoimmunity.

Authors:  A J Slavin; J M Soos; O Stuve; J C Patarroyo; H L Weiner; A Fontana; E K Bikoff; S S Zamvil
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

7.  T cell receptor CDR3 sequence but not recognition characteristics distinguish autoreactive effector and Foxp3(+) regulatory T cells.

Authors:  Xin Liu; Phuong Nguyen; Wei Liu; Cheng Cheng; Meredith Steeves; John C Obenauer; Jing Ma; Terrence L Geiger
Journal:  Immunity       Date:  2009-12-10       Impact factor: 31.745

8.  Preferential Use of Public TCR during Autoimmune Encephalomyelitis.

Authors:  Yunqian Zhao; Phuong Nguyen; Jing Ma; Tianhua Wu; Lindsay L Jones; Deqing Pei; Cheng Cheng; Terrence L Geiger
Journal:  J Immunol       Date:  2016-05-11       Impact factor: 5.422

9.  Multiantigen/multiepitope-directed immune-specific suppression of "complex autoimmune encephalomyelitis" by a novel protein product of a synthetic gene.

Authors:  Ming-Chao Zhong; Nicole Kerlero de Rosbo; Avraham Ben-Nun
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

10.  Peptide-based immunotherapy of experimental autoimmune encephalomyelitis without anaphylaxis.

Authors:  Melanie D Leech; Chen-Yen Chung; Abigail Culshaw; Stephen M Anderton
Journal:  Eur J Immunol       Date:  2007-12       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.